新型组织生物瓣行二叶式主动脉瓣置换术后五年结局
本研究基于COMMENCE前瞻性非随机多中心试验,评估RESILIA组织瓣(Edwards Lifesciences)在原生二叶式主动脉瓣患者中行外科主动脉瓣置换术5年内的安全性和有效性,并与三叶式主动脉瓣患者比较。二叶式主动脉瓣组(n=214)5年内无结构性瓣膜退化,瓣周漏和跨瓣反流发生率低(5年时分别为0.7%和2.9%,均为轻度),结局与三叶式主动脉瓣组(n=458)相似;模型估计的术后平均跨瓣压差和有效瓣口面积及其变化率经年龄、体表面积和生物瓣尺寸校正后两组无差异。
要点
- 二叶式主动脉瓣患者(n=214)5年内无结构性瓣膜退化,瓣周漏和跨瓣反流发生率低(5年时分别为0.7%和2.9%,均为轻度)。
- 二叶式主动脉瓣组患者比三叶式主动脉瓣组年轻十余岁(59.8±12.4岁 vs 70.2±9.5岁;P<.001)。
- 经年龄、体表面积和生物瓣尺寸校正后,模型估计的术后平均跨瓣压差和有效瓣口面积及其变化率在两组间无差异。
核心结论
- 在二叶式主动脉瓣患者中,RESILIA组织瓣至5年显示出极好结局,包括无结构性瓣膜退化和极低的瓣周漏及跨瓣反流发生率,这些结果对RESILIA组织瓣在年轻患者中的耐久性令人鼓舞。
研究设计与样本
- COMMENCE(前瞻性、非随机、多中心)试验中接受研究瓣膜的689例患者,其中645例有记录的原生瓣膜形态和核心实验室可评估的术后超声心动图,用于建模5年血流动力学结局。
- 采用线性混合效应模型估计平均跨瓣压差和有效瓣口面积的纵向变化。
- 二叶式主动脉瓣组214例,三叶式主动脉瓣组458例。
主要发现
- 二叶式主动脉瓣患者(n=214)比三叶式主动脉瓣患者(n=458)年轻十余岁(59.8±12.4岁 vs 70.2±9.5岁;P<.001)。
- 二叶式主动脉瓣队列5年内无结构性瓣膜退化,5年时瓣周漏和跨瓣反流发生率分别为0.7%和2.9%(均为轻度),与三叶式主动脉瓣患者相似。
- 经年龄、体表面积和生物瓣尺寸校正后,模型估计的术后平均跨瓣压差和有效瓣口面积及其变化率在两组间无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study investigated the safety and effectiveness of surgical aortic valve replacement with RESILIA tissue (Edwards Lifesciences) through 5 years in patients with native bicuspid aortic valves. Outcomes were compared with those for patients with tricuspid aortic valves. METHODS: Of 689 patients from the COMMENCE (ProspeCtive, nOn-randoMized, MulticENter) trial who received the study valve, 645 had documented native valve morphology and core laboratory-evaluable echocardiograms from any postoperative visit, which were used to model hemodynamic outcomes over 5 years. Linear mixed-effects models were used to estimate longitudinal changes in mean gradient and effective orifice area. RESULTS: Patients with native bicuspid aortic valves (n = 214) were more than a decade younger than those with tricuspid aortic valves (n = 458; 59.8 ± 12.4 years vs 70.2 ± 9.5 years; P < .001). The bicuspid aortic valve cohort exhibited no structural valve deterioration over 5 years, and rates of paravalvular leak and transvalvular regurgitation were low (0.7% and 2.9%, respectively [all mild] at 5 years). These outcomes mirrored those in patients with native tricuspid aortic valves. The model-estimated postoperative mean gradient and effective orifice area, as well as the rate of change of these outcomes, adjusted for age, body surface area, and bioprosthesis size, did not differ between the 2 cohorts. CONCLUSIONS: Among patients with bicuspid aortic valves, RESILIA tissue valves demonstrated excellent outcomes to 5 years, including no structural valve deterioration and very low rates of paravalvular and transvalvular regurgitation. These results are encouraging for RESILIA tissue durability in young patients.
引用
- Bavaria JE, Mumtaz MA, Griffith B, et al. Five-Year Outcomes After Bicuspid Aortic Valve Replacement With a Novel Tissue Bioprosthesis. Ann Thorac Surg. 2023. PMID: 38135262. doi:10.1016/j.athoracsur.2023.11.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。